Mangoceuticals, Inc. (MGRX) Fair Value 2026

MGRX · Health Information Services ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (53/100)

Quick Summary — As of 2026-08-28, Mangoceuticals, Inc. (MGRX) trades at $0.40. QOC: 4.8/10. Value Trap Risk: 53/100 (WARN). 1/13 models active.

Key Facts

Ticker
MGRX
Price
$0.40
Quality Score
4.8/10
Value Trap Risk
53/100
Models Active
1/13
Last Updated
Strength: ML-RIV suggests +139.9% upside with 46% confidence
Risk: Value Trap score of 53 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give MGRX?

1 Intrinsic Value Models vs. Current Price ($0.40)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.96 +139.9%

All Models Active

All 1 models are displayed above.

What Is Mangoceuticals, Inc. (MGRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Mangoceuticals, Inc.. Trading at $0.40 against an estimated intrinsic value of $0.96, 1 of 1 active models flag meaningful upside of +139.9% at the median.

What Do the Models Say About MGRX?

1 of 13 models are currently active for MGRX. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does MGRX Rank in Health Information Services?

Among 55 Health Information Services stocks, MGRX ranks #43 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Health Information Services Stocks →

Mangoceuticals, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is MGRX a Value Trap?

CirclFi's Value Trap algorithm assigns MGRX a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Mangoceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Mangoceuticals, Inc. earns a quality score of 4.8/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MGRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MGRX's 1 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Mangoceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Health Information Services Stocks Should You Also Analyze?

10 related Health Information Services stocks with 13-model coverage

LGMKLogicMark, Inc.QOC 4.9WORXSCWorx CorpQOC 4.8BRGXBioRegenx, Inc.QOC 5.1VSEEVSee Health, Inc.QOC 4.8ACONAclarion, Inc.QOC 5.1ONMDOneMedNet CorporationQOC 4.8DOCSDoximity, Inc.QOC 9.6LFMDLifeMD, Inc.QOC 7.5CARLCarlsmed, Inc.QOC 6.3HQYHealthEquity, Inc.QOC 9.5

Read investment analysis: LGMK · WORX · BRGX · VSEE · ACON · ONMD · DOCS · LFMD · CARL · HQY

Which Other Stocks Have a Similar Quality Score to MGRX?

6 companies across all industries closest to MGRX’s Quality of Company score of 4.8/10.

GECCGreat Elm Capital Corp.QOC 4.8HTOOFusion Fuel Green PLCQOC 4.8TAAGThe Awareness Group IncQOC 4.8ELVRElevra Lithium LimitedQOC 4.8APREAprea Therapeutics, Inc.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GECC · HTOO · TAAG · ELVR · APRE · NVDA

Where Does MGRX Sit in CirclFi's Health Information Services Rankings?

MGRX is ranked against every other Health Information Services stock CirclFi covers in each of these screens.

See all Health Information Services stocks ranked →

What Else Do Investors Ask About Mangoceuticals, Inc.’s Valuation?

What is Mangoceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Mangoceuticals, Inc. (MGRX). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MGRX overvalued or undervalued right now?

At $0.40, 1 of 1 active models suggest MGRX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Mangoceuticals, Inc.'s business model in Health Information Services.

What does a Quality of Company score of 4.8 mean for MGRX?

Mangoceuticals, Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on MGRX?

CirclFi analyzes MGRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is MGRX a value trap in 2026?

Mangoceuticals, Inc.'s Value Trap score is 53/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Mangoceuticals, Inc. (MGRX) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/MGRX/ · Methodology
Primary sources for this MGRX valuation
  • Financial statements: Mangoceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001938046) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MGRX as of ; valuations recomputed .